Related Experiment Video

Updated: May 17, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Beta-D-glucoside protects against advanced glycation end products (AGEs)-mediated diabetic responses by suppressing

Sidhartha K Mahali1, Sunil K Manna

  • 1Laboratory of Immunology, Centre for DNA Fingerprinting & Diagnostics, Nampally, Hyderabad 500001, India.

Biochemical Pharmacology
|October 13, 2012
PubMed

Insights

Advanced glycation end products (AGEs) impair the activity of peroxisome proliferator-activated receptor gamma (PPARγ), a key factor in diabetes. Mangiferin, however, protects PPARγ activity and shows potential as a diabetes therapeutic.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced glycation end products (AGEs) accumulate due to excess glucose, negatively impacting diabetic patients and aging individuals.
  • Peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor crucial for metabolic regulation, often downregulated in diabetes.

Purpose of the Study:

  • To investigate the inhibitory effects of AGEs on PPARγ activity.
  • To explore the potential of mangiferin as a therapeutic agent against AGE-induced PPARγ dysfunction in diabetes.

Main Methods:

  • Cell-based assays to assess PPARγ activity in the presence of AGEs and PPARγ activators.
  • Analysis of PPARγ translocation, ERK phosphorylation, and NF-κB activation.
  • In silico and in vitro DNA-binding assays for mangiferin-PPARγ interaction.

Main Results:

  • AGEs were found to inhibit PPARγ activity and induce its translocation from the nucleus to the cytoplasm, linked to ERK activation.
  • Antioxidants ineffective against AGE-mediated PPARγ decrease.
  • Mangiferin prevented AGE-induced PPARγ activity reduction, inhibited ERK phosphorylation, and blocked PPARγ cytoplasmic translocation.
  • Mangiferin demonstrated interaction with PPARγ, enhancing its DNA-binding activity.

Conclusions:

  • Mangiferin mitigates AGE-induced cellular damage by inhibiting ERK activation and preventing PPARγ cytoplasmic translocation.
  • Mangiferin's dual action of enhancing PPARγ DNA binding and protecting against AGEs makes it a promising candidate for novel diabetes therapies.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...